According to the Zhitong Finance App, Tianda Pharmaceutical (00455) issued an announcement. Tianda Pharmaceutical (Yunnan) Co., Ltd. (Yunnan Pharmaceutical), a wholly-owned subsidiary of the company, has obtained a drug registration certificate for “injectable nicordil” issued by the China National Drug Administration.
The main component of this product is nicordil, which is a freeze-dried powder injection form. Its indications are mainly acute coronary syndromes such as unstable angina pectoris. Nicordil is a first-line medication for coronary microvascular angina. It can effectively dilate the coronary arteries and works quickly. It has been included in various treatment guidelines such as the “Guidelines for Rational Use of Coronary Artery Disease (2nd Edition)”, “Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevated Acute Coronary Syndrome”, and “Guidelines for Rational Use of ST Segment Elevated Myocardial Infarction”.
The product is declared according to the 3 types of chemical registration. After obtaining the drug registration certificate, it is treated as if it has passed the consistency evaluation. The approval of the drug will further enrich and improve the company's product portfolio and strengthen the company's advantages in the cardiovascular and cerebrovascular fields. After several years of R&D investment and accumulation, the company's R&D has entered the harvest period. Including injectable nicordil, a total of 7 new varieties are expected to be launched in 2024 and 2025, laying a solid foundation for steady future development.